SMTL ID : 5fee.1

EGFR kinase domain T790M mutant in complex with a covalent aminobenzimidazole inhibitor.

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.70 Å

Oligo State

monomer

Ligands

1 x 5X4: ~{N}-[7-methyl-1-[(3~{R})-1-propanoylazepan-3-yl]benzimidazol-2-yl]-3-(trifluoromethyl)benzamide(Covalent)

5X4.1: 16 residues within 4Å: Chain A: L.24, V.32, A.49, K.51, C.81, M.96, Q.97, L.98, M.99, P.100, G.102, C.103, D.106, R.147, L.150, T.160 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:V.32, A:V.32, A:A.49, A:M.96, A:L.150 Hydrogen bonds: A:M.99, A:C.103

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lelais, G. et al., Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. J.Med.Chem. (2016)

Release Date

2016-07-27

Peptides

Epidermal growth factor receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Epidermal growth factor receptor

Related Entries With Identical Sequence